ACOG Does Not Recommend 17-Alpha-Hydroxyprogesterone Caproate for Short Cervix Without Prior Preterm Birth
ACOG and SMFM explicitly recommend AGAINST using 17-alpha-hydroxyprogesterone caproate (17-OHPC) for women with a short cervix who do NOT have a history of spontaneous preterm birth 1.
Current Guideline Recommendations
The most recent 2024 SMFM guideline is unequivocal on this point:
- For women WITHOUT prior spontaneous preterm birth who have a short cervix (≤25 mm): 17-OHPC should NOT be prescribed (GRADE 1B recommendation) 1
- Vaginal progesterone is the recommended treatment for this population 1
The Evidence Behind This Recommendation
Why 17-OHPC Doesn't Work for Short Cervix Alone
A large multicenter trial specifically tested 17-OHPC in women with cervical length <30 mm at 16-22 weeks who had NO history of preterm birth 1. The results showed:
- No difference in preterm birth rates (25.1% vs 24.2% for placebo)
- No improvement in neonatal outcomes
- This led to the strong recommendation against its use in this population
What DOES Work: Vaginal Progesterone
For women with short cervix and no prior preterm birth, the evidence strongly supports vaginal progesterone 1:
- Cervical length ≤20 mm before 24 weeks: vaginal progesterone is recommended (GRADE 1A - highest level of evidence)
- Cervical length 21-25 mm: vaginal progesterone should be considered based on shared decision-making (GRADE 1B)
- Formulations: 90-mg gel or 200-mg micronized capsules daily
When IS 17-OHPC Recommended?
The 2012 SMFM guidelines (which remain the standard for this specific population) clearly state that 17-OHPC is ONLY recommended for 2:
Singleton gestations WITH prior spontaneous preterm birth between 20-36 6/7 weeks:
- Dose: 250 mg intramuscularly weekly
- Timing: Start at 16-20 weeks, continue until 36 weeks
- This remains the only FDA-approved indication (though the drug was recently withdrawn from the market in 2023)
Critical Distinction in Guidelines
The guidelines make a sharp distinction based on prior preterm birth history:
| Population | Recommended Progesterone |
|---|---|
| Prior spontaneous PTB + normal cervix | 17-OHPC weekly IM [2] |
| Prior spontaneous PTB + short cervix | Continue 17-OHPC; consider cerclage [2] |
| NO prior PTB + short cervix ≤20 mm | Vaginal progesterone daily [1] |
| NO prior PTB + short cervix 21-25 mm | Consider vaginal progesterone [1] |
Common Pitfall to Avoid
Do not confuse the two populations. The evidence for 17-OHPC in women with prior preterm birth does NOT translate to women with short cervix alone. These are distinct clinical scenarios with different underlying pathophysiology and different treatment responses.
Post-2023 Update
Following the FDA withdrawal of 17-OHPC in April 2023 due to lack of efficacy in confirmatory trials, SMFM reinforced that 17-OHPC, including compounded formulations, should not be prescribed for treatment of short cervix 1. This makes the distinction even more important, as vaginal progesterone remains the evidence-based option for short cervix without prior preterm birth.